Published: 5. September, 2022
First patient has been dosed in pivotal trial of lead candidate CT001 The pivotal…
- First patient has been dosed in pivotal trial of lead candidate CT001
- The pivotal trial, trial 0205, will investigate the postoperative analgesic efficacy of CT001, in adult participants following impacted mandibular third molar extraction, a randomised, double-blind placebo controlled trial with 220 patients.
- Patient recruitment has now started, and we anticipate to finalise recruitment by the first part of 2023.
Comment from Jes Trygved, CEO of Cessatech
We are very pleased with the initiation of this important trial, and the company is now moving into a different stage with its pivotal study – great work and effort by all the people involved in the preparation and initiation of this trial. CT001 is getting closer to the market and its potential patients and the period ahead will be extremely interesting